PRO 1200
Alternative Names: PRO-1200Latest Information Update: 27 May 2024
At a glance
- Originator ProfoundBio
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 21 May 2024 ProfoundBio has been acquired by Genmab
- 19 Jul 2021 Early research in Solid tumours in China (Parenteral) (ProfoundBio pipeline, July 2021)